Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Effect of Aspirin vs Placebo on the Prevention of Depression in Older People: A Randomized Clinical Trial

    Access Status
    Fulltext not available
    Authors
    Berk, M.
    Berk, M.
    Woods, R.L.
    Nelson, M.R.
    Shah, R.C.
    Reid, C.M.
    Reid, Christopher
    Storey, E.
    Fitzgerald, S.
    Lockery, J.E.
    Wolfe, R.
    Mohebbi, M.
    Mohebbi, M.
    Dodd, S.
    Murray, A.M.
    Stocks, N.
    Fitzgerald, P.B.
    Mazza, C.
    Agustini, B.
    McNeil, J.J.
    Date
    2020
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Berk, M. and Berk, M. and Woods, R.L. and Nelson, M.R. and Shah, R.C. and Reid, C.M. and Reid, C.M. et al. 2020. Effect of Aspirin vs Placebo on the Prevention of Depression in Older People: A Randomized Clinical Trial. JAMA Psychiatry.
    Source Title
    JAMA Psychiatry
    DOI
    10.1001/jamapsychiatry.2020.1214
    ISSN
    2168-622X
    Faculty
    Faculty of Health Sciences
    School
    School of Public Health
    Funding and Sponsorship
    http://purl.org/au-research/grants/nhmrc/334047
    http://purl.org/au-research/grants/nhmrc/1059660
    http://purl.org/au-research/grants/nhmrc/1045862
    http://purl.org/au-research/grants/nhmrc/1092642
    URI
    http://hdl.handle.net/20.500.11937/80047
    Collection
    • Curtin Research Publications
    Abstract

    © 2020 American Medical Association. All rights reserved. Importance: Depression is associated with increased inflammation, which may precede its onset, especially in older people. Some preclinical data suggest potential antidepressant effects of aspirin, supported by limited observational data suggesting lower rates of depression in individuals treated with aspirin. There currently appears to be no evidence-based pharmacotherapies for the primary prevention of depression. Objective: To determine whether low-dose aspirin (100 mg) reduces the risk of depression in healthy older adults. Design, Setting, and Participants: This double-blinded, placebo-controlled randomized clinical trial was a substudy of the Aspirin in Reducing Events in the Elderly (ASPREE) trial, which examined if aspirin increased healthy life span, defined as survival free of dementia and disability. The prespecified secondary outcome was depression. Individuals of all races/ethnicities older than 70 years in Australia, as well as white individuals older than 70 years and black and Hispanic individuals older than 65 years in the United States, were included. Interventions: Participants were randomized to aspirin (100 mg daily) or placebo, with a median (interquartile range) follow-up of 4.7 (3.5-5.6) years. Main Outcomes and Measures: The primary outcome was a proxy measure of major depressive disorder defined as a score of 8 or more on the Center for Epidemiologic Studies Depression 10-item (CES-D-10) scale. Results: Of the 19114 participants enrolled in the trial, 9525 received aspirin and 9589 received a placebo. The mean (SD) age was 75.2 (4.0) years in the aspirin group and 75.1 (4.5) years in the placebo group; 9531 (56.4%) were women. Participants' demographics and clinical characteristics at baseline were similar between groups. A total of 79886 annual CES-D-10 measurements were taken, with a mean of 4.2 measurements per participant. There were no significant differences at annual visits in the proportions of CES-D-10 scores of 8 or more between the aspirin and placebo groups. The incidence rate of new CES-D-10 scores of 8 or more was 70.4 events per 1000 person-years in the aspirin group and 69.1 in the placebo group (hazard ratio, 1.02 [95% CI, 0.96-1.08]; P =.54). Conclusions and Relevance: Low-dose aspirin did not prevent depression in this large-scale study of otherwise healthy older adults. Trial Registration: ClinicalTrials.gov Identifier: NCT01038583.

    Related items

    Showing items related by title, author, creator and subject.

    • Effect of aspirin on disability-free survival in the healthy elderly
      McNeil, J.; Woods, R.; Nelson, M.; Reid, Christopher; Kirpach, B.; Wolfe, R.; Storey, E.; Shah, R.; Lockery, J.; Tonkin, A.; Newman, A.; Williamson, J.; Margolis, K.; Ernst, M.; Abhayaratna, W.; Stocks, N.; Fitzgerald, S.; Orchard, S.; Trevaks, R.; Beilin, L.; Donnan, G.; Gibbs, P.; Johnston, C.; Ryan, J.; Radziszewska, B.; Grimm, R.; Murray, A. (2018)
      Background: Information on the use of aspirin to increase healthy independent life span in older persons is limited. Whether 5 years of daily low-dose aspirin therapy would extend disabilityfree life in healthy seniors ...
    • Randomized placebo-controlled trial of the effects of aspirin on dementia and cognitive decline.
      Ryan, Joanne; Storey, Elsdon; Murray, Anne M; Woods, Robyn L; Wolfe, Rory; Reid, Christopher ; Nelson, Mark R; Chong, Trevor TJ; Williamson, Jeff D; Ward, Stephanie A; Lockery, Jessica E; Orchard, Suzanne G; Trevaks, Ruth; Kirpach, Brenda; Newman, Anne B; Ernst, Michael E; McNeil, John J; Shah, Raj C; ASPREE Investigator Group (2020)
      OBJECTIVE: To determine the effect of low-dose aspirin vs placebo on incident all-cause dementia, incident Alzheimer disease (AD), mild cognitive impairment (MCI), and cognitive decline in older individuals. METHODS: ...
    • Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study
      McNeil, J.; Woods, R.; Nelson, M.; Murray, A.; Reid, Christopher; Kirpach, B.; Storey, E.; Shah, R.; Wolfe, R.; Tonkin, A.; Newman, A.; Williamson, J.; Lockery, J.; Margolis, K.; Ernst, M.; Abhayaratna, W.; Stocks, N.; Fitzgerald, S.; Trevaks, R.; Orchard, S.; Beilin, L.; Donnan, G.; Gibbs, P.; Johnston, C.; Grimm, R.; ASPREE Investigator Group (2017)
      Background: There are no primary prevention trials of aspirin with relevant geriatric outcomes in elderly people. ASPirin in Reducing Events in the Elderly (ASPREE) is a placebo-controlled trial of low-dose aspirin that ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.